Technology

InVita Healthcare Technologies Announces Successful Launch of iReferral with the University of Arkansas for Medical Sciences and the Arkansas Regional Organ Recovery Agency to Automate Organ and Tissue Donor Referrals

Published

2 years ago

September 3, 2024

iReferral® streamlines the referral process by automating the identification of potential organ and tissue donors in the hospital and electronically notifying the Organ Procurement Organization (OPO).

LITTLE ROCK, Ark., Sept. 3, 2024 /PRNewswire/ — The University of Arkansas for Medical Sciences (UAMS) partnered with InVita Healthcare Technologies (InVita) and Arkansas Regional Organ Recovery Agency (ARORA), the federally designated OPO serving nearly the entire state of Arkansas, to successfully launch iReferral to improve the critical first step of the life-saving organ and tissue transplantation workflow.

This achievement will save countless hours for those involved in the referral process and ultimately save more lives.

Using advanced technology, iReferral replaces the outdated and time-consuming process of telephonic organ and tissue donor notification to a hospital’s federally designated OPO with a modern, real-time, and secure electronic interface. This interoperability directly delivers the donor referral to iTransplant®, the OPO’s electronic donor management record provided by InVita, allowing nurses to focus their valuable time on providing care and support for their critically ill patients and families while supporting the life-saving mission of organ and tissue donation and transplantation.

“This effort builds on UAMS’ long partnership with ARORA to provide life-saving organ and tissue donations to transplant recipients,” said Dr. David Warner, Chairman of CORE (Committed to Organ, Tissue, and Eye Recovery Education) Committee, UAMS. “By collaborating with InVita, we are using technology to ensure we can properly identify all potential donors and make the referral process more efficient. This allows physicians and nurses to spend more time with patients, where they are most needed.”

The timely and direct delivery of a potential donor from the hospital’s electronic health record system directly to the OPO’s iTransplant system via iReferral provides the OPO with appropriate notice to ensure that all families are offered the opportunity to make a decision that will save lives through organ and tissue donation. As hundreds of hospitals across the country partner with their designated OPO to adopt this technology, ARORA continues to be an innovative leader as this is their third hospital system implementation of this key technology.

“We are excited to be collaborating with UAMS in our recent launch of iReferral,” said Jeremy Lemmons, Manager of Hospital Development, ARORA. “This has proven to be a great asset in its ability to ease the burden on the healthcare providers while allowing ARORA to maximize its impact on those waiting on a life-saving transplant.”

“This achievement will save countless hours for those involved in the referral process and ultimately save more lives through organ and tissue donation,” said Amelia Nabholz, Director of Hospital Development, ARORA.

With more than 100,000 individuals awaiting a life-saving organ, Centers for Medicare & Medicaid Services (CMS) regulations mandate hospitals refer all potential organ and tissue donors to their federally designated OPO. Each donor has the ability to save up to eight (8) lives through organ transplantation and enhance over seventy-five (75) more through tissue donation. iReferral directly improves regulatory compliance to these federal mandates that are in place to provide hope to those waiting for a life-saving organ and/or tissue transplant.

“It is our long-standing goal at InVita to provide innovative technology solutions for our partners that improve process inefficiencies and regulatory compliance,” said Wade Liu, InVita Healthcare Technology’s Chief Product Officer and General Manager of its Donation and Transplant Division. “We’re honored to support the mission of ensuring all donors and families have the opportunity to donate life to the many waiting and in need.”

ARORA| arora.org
ARORA is a non-profit, independent organ procurement agency that was established in 1987. It is headquartered in Little Rock, Arkansas with a regional office in Fayetteville, Arkansas. ARORA’s mission is to restore lives by recovering organs and tissues for transplant. For those listed on the organ transplant waiting list, ARORA is a bridge to new life. For those in need of tissue transplants, ARORA is an agent of restored sight, mobility, ability, and freedom from pain.

About InVita Healthcare Technologies | invitahealth.com
InVita provides mission-critical and chain-of-custody software technologies for complex medical, forensic, and community care environments. InVita’s solutions streamline clinical workflows, optimize supply chains, sample tracking, and visibility across donation and transplantation, blood and plasma operations, the tissue and implant lifecycle, and environments spanning DNA and forensics. InVita continues to expand the iReferral® and iTransplant® platforms supporting nearly 75% of all OPOs in the United States and used by more than 15,000 medical professionals across more than 100 organ, tissue, eye, and birth tissue organizations around the world.

View original content to download multimedia:https://www.prnewswire.com/news-releases/invita-healthcare-technologies-announces-successful-launch-of-ireferral-with-the-university-of-arkansas-for-medical-sciences-and-the-arkansas-regional-organ-recovery-agency-to-automate-organ-and-tissue-donor-referrals-302237097.html

SOURCE InVita Healthcare Technologies

Technology

Baidu to Report First Quarter 2026 Financial Results on May 18, 2026

Published

3 minutes ago

April 23, 2026

BEIJING, April 23, 2026 /PRNewswire/ — Baidu, Inc. (Nasdaq: BIDU; HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)) (“Baidu” or the “Company”), a leading AI company with strong Internet foundation, today announced that it will report its financial results for the First Quarter 2026 ended March 31, 2026, before the U.S. market opens on May 18, 2026. Baidu’s management will hold an earnings conference call at 8:00 AM on May 18, 2026, U.S. Eastern Time (8:00 PM on May 18, 2026, Beijing Time).

Please register in advance of the conference call using the link provided below. It will automatically direct you to the registration page of “Baidu Inc. Q1 2026 Earnings Conference Call”. Please follow the steps to enter your registration details, then click “Register”. Upon registering, you will then be provided with the dial-in number, the passcode, and your unique access PIN. This information will also be emailed to you as a calendar invite.

For pre-registration, please click:
https://s1.c-conf.com/diamondpass/10054331-iu876y.html

In the 10 minutes prior to the call start time, you may use the conference access information (including dial-in number(s), the passcode and unique access PIN) provided in the calendar invite that you have received following your pre-registration.

Additionally, a live and archived webcast of this conference call will be available at https://ir.baidu.com.

A replay of the conference call may be accessed by phone at the following number until May 25, 2026:
US: 1 855 883 1031
Reply PIN: 10054331

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under “BIDU” and the HKEX under “9888.” One Baidu ADS represents eight Class A ordinary shares.

View original content:https://www.prnewswire.com/news-releases/baidu-to-report-first-quarter-2026-financial-results-on-may-18-2026-302751204.html

SOURCE Baidu, Inc.

Technology

Phase 1 of 139th Canton Fair Introduces New Dedicated Product Zones as Emerging Technologies Take Center Stage

Published

3 minutes ago

April 23, 2026

GUANGZHOU, China, April 23, 2026 /PRNewswire/ — The 139th China Import and Export Fair (Canton Fair) has further optimized its exhibition landscape with nine new dedicated product zones, reflecting ongoing structural shifts in global trade and the continued upgrading of China’s export portfolio.

Among the most closely watched additions in Phase 1 are the consumer and agricultural drone zones, both making their debut at the Canton Fair and offering a focused showcase of applications in the low‑altitude economy. The consumer drone zone showcases progress in flight control, AI‑based obstacle avoidance and energy efficiency across imaging, tourism, emergency response and patrol. The agricultural drone zone highlights precision farming, with spraying, seeding and field‑management demonstrations showing terrain‑following, intelligent route planning, and precise payload control.

On day one, a Shandong‑based drone manufacturer welcomed buyers from 30+ countries, with over 50 strong leads. One buyer, after seeing load and wind‑resistance demonstrations, immediately confirmed three sample units and even proposed becoming a regional distributor.

Display technology is another focal point of Phase 1, highlighting advances in color accuracy, energy efficiency, and overall visual performance. Developments in fine‑grained control, expanded color gamut, and reduced power consumption point to a clear trend toward immersive viewing experiences combined with sustainability gains.

The smart wearables zone underscores how intelligent devices are becoming key interfaces for human‑machine interaction. From real‑time language translation and adaptive noise cancellation to long‑term health monitoring and AI‑enabled eyewear, wearables are evolving from standalone products into integrated systems that support communication, well‑being, and productivity across daily and professional settings.

The service robots zone further illustrates how artificial intelligence is moving from conceptual exploration to large‑scale deployment. Advanced robots showcased across industrial, commercial, medical, and public‑service scenarios demonstrate growing autonomy, multi‑sensory perception, and closer human-robot collaboration.

By bringing emerging technologies into clearer focus through dedicated zones, the 139th Canton Fair is reinforcing its function as a platform where trade trends take shape, innovation meets application, and global buyers gain early insights into cutting-edge technologies.

For pre-registration, please click: https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

Photo – https://mma.prnewswire.com/media/2963958/1.jpg

View original content:https://www.prnewswire.co.uk/news-releases/phase-1-of-139th-canton-fair-introduces-new-dedicated-product-zones-as-emerging-technologies-take-center-stage-302751520.html

Technology

OZMOSI Announces Strategic Partnership with Planview to Advance AI-Driven Planning in Pharmaceutical R&D

Published

3 minutes ago

April 23, 2026

By combining structured clinical intelligence with AI-driven portfolio planning, the partnership gives pharmaceutical teams a faster, clearer way to make high-stakes R&D decisions

SPRING LAKE HEIGHTS, N.J., April 23, 2026 /PRNewswire/ — OZMOSI, a leading provider of structured pharmaceutical development intelligence, today announced a strategic partnership with Planview, the leading AI-powered end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD).

By integrating OZMOSI’s machine-readable clinical datasets directly into Planview’s AI-driven portfolio planning platform, external scientific data is now connected to internal R&D planning in one system, helping pharmaceutical organizations better predict market shifts, prioritize R&D investments, and make faster, more confident decisions.

This integration brings external clinical reality into internal R&D decision-making, so teams can plan based on what’s actually happening, not just on what they hope will happen.

The two organizations combine deep expertise in complementary areas, united by a shared focus on improving the quality and usability of data for strategic decision-making. OZMOSI provides structured, machine-readable intelligence across clinical trials, drug development programs, regulatory activity, and scientific literature, built on a consistent taxonomy that standardizes how data is connected and understood. Planview’s platform enables organizations to model complex investment scenarios, align initiatives with corporate strategy, and optimize resource allocation.

Together, these capabilities give teams a clearer, more complete view of the R&D landscape, grounded in clean, standardized data and strengthened by AI-driven analysis.

“AI is only as powerful as the data that fuels it,” said Beau Bush, President and Founder of OZMOSI. “Pharmaceutical organizations have no shortage of data, but too often it’s fragmented, inconsistent, and difficult to operationalize. By bringing OZMOSI’s structured data foundation together with Planview’s AI-driven planning capabilities, we’re enabling teams to move beyond disconnected analysis and toward truly integrated, forward-looking decision-making.”

“Strategic planning in pharmaceutical R&D is becoming increasingly dependent on advanced analytics and AI,” said Louise Allen, Chief Product Officer at Planview. “Integrating OZMOSI’s clinical intelligence into Planview’s platform enables pharmaceutical leaders to make better decisions by combining trusted external data with AI-driven planning

OZMOSI’s dataset spans more than 800,000 clinical trials, over 35,000 drugs, and 4,000 diseases and conditions. It brings together insights from clinical trial registries, regulatory filings, scientific literature, company disclosures, and industry announcements into a unified, structured dataset.

When integrated into Planview’s platform, this intelligence enables pharmaceutical and biotech organizations to evaluate competitive landscapes, identify emerging clinical trends, and simulate portfolio outcomes with unprecedented precision.

Together, OZMOSI and Planview are redefining how pharmaceutical organizations approach R&D strategy, ensuring that investment decisions are guided by accurate, standardized, and AI-ready data. By combining internal portfolio visibility with a continuously updated external view of the market, the partnership helps leaders not only understand what they have, but what to do next.

About OZMOSI

Founded in 2013, OZMOSI specializes in transforming complex pharmaceutical R&D intelligence into structured, machine-readable data. The company provides the foundation needed for accurate competitive analysis, product forecasting, and portfolio strategy. Through its proprietary taxonomy and semantic layer, OZMOSI connects fragmented data across the pharmaceutical ecosystem, enabling faster, more confident decision-making for global pharma, biotech, and investment teams.

Based in Spring Lake Heights, New Jersey, OZMOSI is focused on making pharmaceutical intelligence clear, usable, and ready for the future of AI-driven strategy. Learn more at www.ozmosi.com.

About Planview

Planview is the leading end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD), powered by advanced AI capabilities that give business and technology leaders the strategic foresight to prioritize investments and initiatives, make plans real within constraints, and pivot with certainty when things change. Our AI-driven connected platform of solutions underpins the business and digital transformations of more than 3,000 customers and 3.1 million users globally. Headquartered in Austin, Texas, Planview has over 1,500 employees worldwide. Learn more at www.planview.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/ozmosi-announces-strategic-partnership-with-planview-to-advance-ai-driven-planning-in-pharmaceutical-rd-302750944.html

SOURCE Ozmosi Company